114 related articles for article (PubMed ID: 33039969)
1. The effect of genetic variations for interleukin-10 (IL-10) on the efficacy of immunosuppressive therapy in patients after kidney transplantation.
Bogacz A; Polaszewska A; Bartkowiak-Wieczorek J; Tejchman K; Dziewanowski K; Ostrowski M; Czerny B; Grześkowiak E; Sieńko M; Machaliński B; Sieńko J; Kotowski M
Int Immunopharmacol; 2020 Dec; 89(Pt A):107059. PubMed ID: 33039969
[TBL] [Abstract][Full Text] [Related]
2. Influence of TGFB1 and CTLA4 polymorphisms on calcineurin inhibitors dose and risk of acute rejection in renal transplantation.
Bogacz A; Wolek M; Sieńko J; Czerny B; Machaliński B; Olbromski P; Kotowski M
Sci Rep; 2021 Sep; 11(1):17531. PubMed ID: 34475433
[TBL] [Abstract][Full Text] [Related]
3. IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients.
Liu MZ; He HY; Zhang YL; Hu YF; He FZ; Luo JQ; Luo ZY; Chen XP; Liu ZQ; Zhou HH; Shao MJ; Ming YZ; Xin HW; Zhang W
Acta Pharmacol Sin; 2017 Mar; 38(3):415-423. PubMed ID: 28112181
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
5. Genetic association of interleukin-2, interleukin-4, interleukin-6, transforming growth factor-β, tumour necrosis factor-α and blood concentrations of calcineurin inhibitors in Turkish renal transplant patients.
Seyhun Y; Ciftci HS; Kekik C; Karadeniz MS; Tefik T; Nane I; Turkmen A; Oguz FS; Aydin F
Int J Immunogenet; 2015 Jun; 42(3):147-60. PubMed ID: 25817300
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
[TBL] [Abstract][Full Text] [Related]
7. The influence of the tumor necrosis factor-alpa-308G>A polymorphism on the efficacy of immunosuppressive therapy in patients after kidney transplantation.
M Kotowski M; Bogacz A; Bartkowiak-Wieczorek J; Sienko J; Procyk D; Dziewanowski K; Ostrowski M; Czerny B; Grzeskowiak E; Machalinski B
J Physiol Pharmacol; 2016 Dec; 67(6):819-826. PubMed ID: 28195062
[TBL] [Abstract][Full Text] [Related]
8. A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients.
Jannot AS; Vuillemin X; Etienne I; Buchler M; Hurault de Ligny B; Choukroun G; Colosio C; Thierry A; Vigneau C; Moulin B; Rerolle JP; Heng AE; Subra JF; Legendre C; Beaune P; Loriot MA; Thervet E; Pallet N
Ther Drug Monit; 2016 Apr; 38(2):223-9. PubMed ID: 26829596
[TBL] [Abstract][Full Text] [Related]
9. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Pharmacogenet Genomics; 2019 Jan; 29(1):9-17. PubMed ID: 30489455
[TBL] [Abstract][Full Text] [Related]
10. Impact of FOXP3 Polymorphisms on the Blood Level of Tacrolimus in Renal Transplant Recipients.
Ge J; Wang J; Zhao H; Li K; Jing Y; Li G
Transplant Proc; 2016; 48(6):1962-7. PubMed ID: 27569929
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX
Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
[TBL] [Abstract][Full Text] [Related]
12. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
[TBL] [Abstract][Full Text] [Related]
13. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
[TBL] [Abstract][Full Text] [Related]
14. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
[TBL] [Abstract][Full Text] [Related]
15. The Importance of the FUT2 rs602662 Polymorphism in the Risk of Cardiovascular Complications in Patients after Kidney Transplantation.
Kotowski MJ; Ostrowski P; Sieńko J; Czerny B; Tejchman K; Machaliński B; Górska A; Mrozikiewicz AE; Bogacz A
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928269
[TBL] [Abstract][Full Text] [Related]
16. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody.
Gonwa TA; Mai ML; Smith LB; Levy MF; Goldstein RM; Klintmalm GB
Clin Transplant; 2002 Apr; 16(2):144-9. PubMed ID: 11966785
[TBL] [Abstract][Full Text] [Related]
18. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.
Yanik MV; Seifert ME; Locke JE; Hauptfeld-Dolejsek V; Crowley MR; Cutter GR; Mannon RB; Feig DI; Limdi NA
Pediatr Transplant; 2019 Aug; 23(5):e13494. PubMed ID: 31124575
[TBL] [Abstract][Full Text] [Related]
19. FOXP3 rs3761548 polymorphism is associated with tacrolimus-induced acute nephrotoxicity in renal transplant patients.
Wu Z; Xu Q; Qiu X; Jiao Z; Zhang M; Zhong M
Eur J Clin Pharmacol; 2017 Jan; 73(1):39-47. PubMed ID: 27747372
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
